NO304555B1 - FremgangsmÕte for rensing av en uren oppl°sning av aktivt, rekombinant, humant interleukin-4 - Google Patents

FremgangsmÕte for rensing av en uren oppl°sning av aktivt, rekombinant, humant interleukin-4 Download PDF

Info

Publication number
NO304555B1
NO304555B1 NO920351A NO920351A NO304555B1 NO 304555 B1 NO304555 B1 NO 304555B1 NO 920351 A NO920351 A NO 920351A NO 920351 A NO920351 A NO 920351A NO 304555 B1 NO304555 B1 NO 304555B1
Authority
NO
Norway
Prior art keywords
buffer
column
active
sodium chloride
solution
Prior art date
Application number
NO920351A
Other languages
English (en)
Norwegian (no)
Other versions
NO920351D0 (no
NO920351L (no
Inventor
Eric Bonnem
Lee Sullivan
Michael Grace
Loretta Bober
John Chu-Tay Tang
David Naveh
T L Nagabushan
Jay Raman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO920351D0 publication Critical patent/NO920351D0/no
Publication of NO920351L publication Critical patent/NO920351L/no
Publication of NO304555B1 publication Critical patent/NO304555B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Manufacture Of Alloys Or Alloy Compounds (AREA)
NO920351A 1989-07-28 1992-01-27 FremgangsmÕte for rensing av en uren oppl°sning av aktivt, rekombinant, humant interleukin-4 NO304555B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693789A 1989-07-28 1989-07-28
PCT/US1990/004093 WO1991001744A2 (en) 1989-07-28 1990-07-26 Uses of interleukin-4 and method for purifying it

Publications (3)

Publication Number Publication Date
NO920351D0 NO920351D0 (no) 1992-01-27
NO920351L NO920351L (no) 1992-03-27
NO304555B1 true NO304555B1 (no) 1999-01-11

Family

ID=23527716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920351A NO304555B1 (no) 1989-07-28 1992-01-27 FremgangsmÕte for rensing av en uren oppl°sning av aktivt, rekombinant, humant interleukin-4

Country Status (20)

Country Link
EP (3) EP0484380A1 (ja)
JP (2) JP2580391B2 (ja)
KR (1) KR100191223B1 (ja)
AT (2) ATE119395T1 (ja)
AU (2) AU645514B2 (ja)
CA (1) CA2064753A1 (ja)
DE (2) DE69025961T2 (ja)
DK (2) DK0410750T3 (ja)
ES (2) ES2072395T3 (ja)
FI (2) FI981585L (ja)
GR (1) GR3019707T3 (ja)
HK (1) HK185196A (ja)
HU (1) HU215257B (ja)
IL (2) IL95201A0 (ja)
NO (1) NO304555B1 (ja)
OA (1) OA09649A (ja)
RU (1) RU2082756C1 (ja)
SG (1) SG44544A1 (ja)
WO (1) WO1991001744A2 (ja)
ZA (1) ZA905896B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723119A (en) * 1989-07-28 1998-03-03 Schering Corporation Method for enhancing wound healing/repair with IL-4
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
AU660942B2 (en) * 1990-09-13 1995-07-13 Commonwealth Scientific And Industrial Research Organisation Ovine cytokine genes
JPH0747545B2 (ja) * 1991-01-10 1995-05-24 シェリング・コーポレーション 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
JPH07165602A (ja) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd 放射線障害防護剤
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
US6132737A (en) * 1997-09-29 2000-10-17 Revlon Consumer Products Corporation Method for reducing sunburn cell formation with cosmetic compositions containing ascorbic acid
ES2543819T3 (es) * 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
WO2010123798A2 (en) 2009-04-20 2010-10-28 Galenbio, Inc. Compositions for transfection of biomolecules into cells
JP5784416B2 (ja) * 2011-08-26 2015-09-24 出光興産株式会社 菌類の回収方法
EP3995196B1 (en) * 2020-11-04 2023-08-09 Sartorius BIA Separations d.o.o. Purification process for lipid-membrane-enclosed complex assemblages

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4723000A (en) * 1983-07-05 1988-02-02 Biospectrum, Inc. Human interferon gamma and interleukin-2
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
ZA912037B (en) * 1990-03-21 1992-03-25 Schering Corp Use of il-4 to enhance immune response to infectious antigenic challenges

Also Published As

Publication number Publication date
EP0410750A2 (en) 1991-01-30
WO1991001744A3 (en) 1991-04-04
EP0410750B1 (en) 1995-03-08
JPH0940575A (ja) 1997-02-10
EP0618220A1 (en) 1994-10-05
DE69017547D1 (de) 1995-04-13
FI102039B1 (fi) 1998-10-15
FI981585A0 (fi) 1990-07-26
JP2580391B2 (ja) 1997-02-12
JPH04506299A (ja) 1992-11-05
KR100191223B1 (ko) 1999-06-15
FI981585A7 (fi) 1998-07-10
AU6055890A (en) 1991-03-11
FI981585L (fi) 1998-07-10
HK185196A (en) 1996-10-11
ATE135366T1 (de) 1996-03-15
WO1991001744A2 (en) 1991-02-21
FI102039B (fi) 1998-10-15
AU645514B2 (en) 1994-01-20
FI920367A0 (fi) 1992-01-28
GR3019707T3 (en) 1996-07-31
DE69017547T2 (de) 1995-11-02
AU5476194A (en) 1994-06-02
NO920351D0 (no) 1992-01-27
IL95201A0 (en) 1991-06-10
AU661221B2 (en) 1995-07-13
HU9200254D0 (en) 1992-04-28
DE69025961T2 (de) 1996-10-31
HU215257B (hu) 1998-11-30
EP0618220B1 (en) 1996-03-13
DE69025961D1 (de) 1996-04-18
DK0410750T3 (da) 1995-07-10
NO920351L (no) 1992-03-27
DK0618220T3 (da) 1996-07-22
ES2089875T3 (es) 1996-10-01
KR920700670A (ko) 1992-08-10
ATE119395T1 (de) 1995-03-15
CA2064753A1 (en) 1991-01-29
ZA905896B (en) 1991-04-24
IL121897A0 (en) 1998-03-10
OA09649A (en) 1993-05-15
ES2072395T3 (es) 1995-07-16
EP0410750A3 (en) 1991-06-19
RU2082756C1 (ru) 1997-06-27
HUT60146A (en) 1992-08-28
SG44544A1 (en) 1997-12-19
EP0484380A1 (en) 1992-05-13

Similar Documents

Publication Publication Date Title
Lopez et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.
Watson et al. Biochemical and biological characterization of lymphocyte regulatory molecules. I. Purification of a class of murine lymphokines.
Ruef et al. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness
CA1341588C (en) Human ifn-beta2/i1-6, its purification and use
Moreau et al. Characterization of a factor produced by human T cell clones exhibiting eosinophil-activating and burst-promoting activities.
NO304555B1 (no) FremgangsmÕte for rensing av en uren oppl°sning av aktivt, rekombinant, humant interleukin-4
WO2003015697A2 (en) Interleukin-2 mutants with reduced toxicity
NZ202190A (en) Human immune interferon : production by recombinant dna technology
FI103987B (fi) Interleukiini-7
JPH07203967A (ja) 霊長動物造血成長因子の新規種族
CN112618698B (zh) 一种人白细胞介素10-Fc融合蛋白的注射制剂
US5895646A (en) Isolated native primate GM-CSF protein
Chan et al. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells
JP2559035B2 (ja) 細胞生長調節因子
Lotem et al. Clonal variation in susceptibility to differentiation by different protein inducers in the myeloid leukemia cell line M1
AU1055988A (en) Human interleukin-4 muteins
EP1443056A1 (en) IL-6 receptor.IL-6 direct fusion protein
EP0573904B1 (en) Therapeutic agent for neutropenia
IE902718A1 (en) Use of Interleukin-4 for increasing numbers of neutrophils and for treating myeloid or monocytoid leukaemia
CN115850436B (zh) 白介素2突变体及其应用
Bellone et al. Soluble factor (s) released by the PF‐382 T‐cell line enhances the stimulatory effect of monocytes on the BFU‐E growth
CA1341253C (en) Human ifn-.beta.2/il-6, its purification and use
JP3689111B2 (ja) インターロイキン１５
CA1340266C (en) Human pluripotent hematopoietic colony stimulating factor, method of production and use
IE913984A1 (en) Method for increasing and activating monocytes and¹neutrophils and for inducing maturation of myeloid cells¹with interleukin-5

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2001